CHLA-90Homo sapiens (Human)Cancer cell line
Also known as: CHLA90, CH-LA-90
AI Summary
No AI-generated summary available for this cell line.
Basic Information
| Database ID | CVCL_6610 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Bone marrow[UBERON:UBERON_0002371] |
Donor Information
| Age | 8 |
|---|---|
| Age Category | Pediatric |
| Sex | Male |
Disease Information
| Disease | Neuroblastoma |
|---|---|
| Lineage | Peripheral Nervous System |
| Subtype | Neuroblastoma |
| OncoTree Code | NBL |
DepMap Information
| Source Type | Academic lab |
|---|---|
| Source ID | ACH-001481_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Glu286Lys (c.856G>A) | Homozygous | - | PubMed=17332242, PubMed=16960149 |
| MutationUnexplicit | ATRX | Ex2-10del | Hemizygous | - | PubMed=31631027 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Amelogenin
X
CSF1PO
11,12
D13S317
11,13
D16S539
12
D18S51
17
D19S433
14
D21S11
28,30.2
D2S1338
18,24
D3S1358
15,16
D5S818
12,13
D7S820
9,10
D8S1179
11
FGA
20,22
TH01
6
TPOX
8
vWA
18
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines
Loading gene expression data...
Publications
ATRX in-frame fusion neuroblastoma is sensitive to EZH2 inhibition via modulation of neuronal gene signatures.
Segura M.F., Dyer M.A., Bernstein E.
Cancer Cell 36:512-527.e9(2019).
Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations.
Lau L.M.S.
J. Neurooncol. 119:17-26(2014).
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.
Reynolds C.P.
Pediatr. Blood Cancer 56:239-249(2011).
Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3.
Gabbert H.E., Poremba C.
Cancer Res. 64:3395-3405(2004).
Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.
Gomer C.J., Triche T.J., Reynolds C.P.
Cancer Res. 61:6185-6193(2001).
Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma.
Brodeur G.M., White P.S.
Cancer Res. 61:679-686(2001).
Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy.
Keshelava N., Seeger R.C., Groshen S., Reynolds C.P.
Cancer Res. 58:5396-5405(1998).